Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Price, Quote, News and Overview

NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD

8.69  -1.16 (-11.78%)

After market: 9.14 +0.45 (+5.18%)

ACOG Quote, Performance and Key Statistics

ALPHA COGNITION INC

NASDAQ:ACOG (5/22/2025, 8:00:00 PM)

After market: 9.14 +0.45 (+5.18%)

8.69

-1.16 (-11.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap139.21M
Shares16.02M
Float14.49M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-09 2021-06-09


ACOG short term performance overview.The bars show the price performance of ACOG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

ACOG long term performance overview.The bars show the price performance of ACOG in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ACOG is 8.69 USD. In the past month the price increased by 71.74%.

ALPHA COGNITION INC / ACOG Daily stock chart

ACOG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.77 322.91B
AMGN AMGEN INC 13.1 146.19B
GILD GILEAD SCIENCES INC 13.79 132.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.58B
REGN REGENERON PHARMACEUTICALS 13.47 64.44B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.59B
ARGX ARGENX SE - ADR 99.05 35.50B
ONC BEIGENE LTD-ADR 5.93 25.74B
BNTX BIONTECH SE-ADR N/A 23.82B
NTRA NATERA INC N/A 20.73B
SMMT SUMMIT THERAPEUTICS INC N/A 19.14B
BIIB BIOGEN INC 7.98 18.51B

About ACOG

Company Profile

ACOG logo image Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.

Company Info

ALPHA COGNITION INC

c/o 1200 - 750 West Pender Street

Vancouver BRITISH COLUMBIA CA

Employees: 52

ACOG Company Website

ACOG Investor Relations

Phone: 16045649244

ALPHA COGNITION INC / ACOG FAQ

What is the stock price of ALPHA COGNITION INC today?

The current stock price of ACOG is 8.69 USD. The price decreased by -11.78% in the last trading session.


What is the ticker symbol for ALPHA COGNITION INC stock?

The exchange symbol of ALPHA COGNITION INC is ACOG and it is listed on the Nasdaq exchange.


On which exchange is ACOG stock listed?

ACOG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALPHA COGNITION INC stock?

7 analysts have analysed ACOG and the average price target is 20.4 USD. This implies a price increase of 134.75% is expected in the next year compared to the current price of 8.69. Check the ALPHA COGNITION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALPHA COGNITION INC worth?

ALPHA COGNITION INC (ACOG) has a market capitalization of 139.21M USD. This makes ACOG a Micro Cap stock.


How many employees does ALPHA COGNITION INC have?

ALPHA COGNITION INC (ACOG) currently has 52 employees.


What are the support and resistance levels for ALPHA COGNITION INC (ACOG) stock?

ALPHA COGNITION INC (ACOG) has a support level at 7.52. Check the full technical report for a detailed analysis of ACOG support and resistance levels.


Should I buy ALPHA COGNITION INC (ACOG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALPHA COGNITION INC (ACOG) stock pay dividends?

ACOG does not pay a dividend.


What is the Price/Earnings (PE) ratio of ALPHA COGNITION INC (ACOG)?

ALPHA COGNITION INC (ACOG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).


What is the Short Interest ratio of ALPHA COGNITION INC (ACOG) stock?

The outstanding short interest for ALPHA COGNITION INC (ACOG) is 0.25% of its float. Check the ownership tab for more information on the ACOG short interest.


ACOG Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to ACOG.


Chartmill TA Rating
Chartmill Setup Rating

ACOG Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ACOG. ACOG has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACOG Financial Highlights

Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -40.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.85%
ROE -35.3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%62.46%
Sales Q2Q%N/A
EPS 1Y (TTM)-40.09%
Revenue 1Y (TTM)N/A

ACOG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to ACOG. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners39.47%
Ins Owners6.55%
Short Float %0.25%
Short Ratio0.54
Analysts
Analysts82.86
Price Target20.4 (134.75%)
EPS Next Y-3562.5%
Revenue Next YearN/A